SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

December 21, 2025

Study Completion Date

December 21, 2025

Conditions
HER2-positive Advanced Solid Tumors
Interventions
DRUG

SPH5030 tablets

SPH5030 tablets orally once or twice daily.

Trial Locations (17)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

300181

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

Unknown

RECRUITING

Anhui provincial hospital, Hefei

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

Guangxi Cancer Hospital, Nanning

RECRUITING

The Fourth Hospital of Hebei Medical University, Shijiazhuang

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

RECRUITING

Anyang Cancer Hospital, Anyang

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

Xiangyang Central Hospital, Xiangyang

RECRUITING

Jiangsu Province Hospital, Nanjing

RECRUITING

The First Affiliated Hospital of China Medical University, Shenyang

RECRUITING

Linyi Cancer Hospital, Linyi

RECRUITING

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an

RECRUITING

The First Affiliated Hospital of Bengbu Medical University, Bengbu

RECRUITING

The second people's hospital of neijiang, Neijiang

RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY